title: Dabigatran and bleeding: still an emergent situation?
authors.forename: Joel
authors.initials: J
authors.lastname: Van Heukelom
authors.forename: Yasir
authors.initials: Y
authors.lastname: Lal
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D003029:Coagulants / Q000627:therapeutic use; D000069604:Dabigatran; D005169:Factor VIII / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D011516:Prothrombin / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D003029:Coagulants; D011994:Recombinant Proteins; D015091:beta-Alanine; D011516:Prothrombin; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa; D000069604:Dabigatran